{"protocolSection":{"identificationModule":{"nctId":"NCT03753490","orgStudyIdInfo":{"id":"1011455"},"organization":{"fullName":"Uppsala University","class":"OTHER"},"briefTitle":"ABC-Scores for Reduction of Stroke and Mortality in Atrial Fibrillation - The ABC-AF Study","officialTitle":"ABC-Risk Scores for Reduction of Stroke and Mortality in Atrial Fibrillation - a Multicenter, Registry-based, Randomized Controlled Parallel-group Open-label Study","acronym":"ABC-AF"},"statusModule":{"statusVerifiedDate":"2023-06","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-11-25","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-05-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-05-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2018-11-08","studyFirstSubmitQcDate":"2018-11-21","studyFirstPostDateStruct":{"date":"2018-11-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-06-20","lastUpdatePostDateStruct":{"date":"2023-06-22","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Uppsala University","class":"OTHER"},"collaborators":[{"name":"Swedish Foundation for Strategic Research","class":"OTHER"},{"name":"Swedish Heart Lung Foundation","class":"OTHER"},{"name":"Roche Diagnostics","class":"INDUSTRY"},{"name":"The Swedish Research Council","class":"OTHER_GOV"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The primary study objective is to evaluate if personalized treatment by decision support, based on the biomarker-based risk prediction (ABC-scores) guided strategy, reduces the occurrence of the composite outcome of stroke or death in patients with atrial fibrillation. Approximately 6500 patients will be randomized 1:1 to ABC risk score guided therapy or standard care."},"conditionsModule":{"conditions":["Atrial Fibrillation"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":3933,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"ABC score guided therapy","type":"OTHER","description":"Individual treatment recommendations based on the ABC-scores for stroke and bleeding.","interventionNames":["Other: ABC score guided therapy"]},{"label":"Standard care","type":"OTHER","description":"Management according to local practice, national and international guidelines.","interventionNames":["Other: Standard care"]}],"interventions":[{"type":"OTHER","name":"ABC score guided therapy","description":"In the ABC arm, individual treatment recommendations based on the ABC-scores for stroke and bleeding including non-vitamin K oral anticoagulant or no anticoagulant treatment, and other drugs and interventions, to improve stroke free survival.","armGroupLabels":["ABC score guided therapy"]},{"type":"OTHER","name":"Standard care","description":"In the standard care arm, management according to local practice, national and international guidelines, including the potential use of traditional clinical risk scores for stroke and/or bleeding, anticoagulant treatment and other treatments and interventions.","armGroupLabels":["Standard care"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Composite of Stroke or Death","timeFrame":"From the date of enrolment through study completion, minimum follow-up 2 years."}],"secondaryOutcomes":[{"measure":"Major Bleeding","timeFrame":"From the date of enrolment through study completion, minimum follow-up 2 years."},{"measure":"Stroke","timeFrame":"From the date of enrolment through study completion, minimum follow-up 2 years."},{"measure":"Death","timeFrame":"From the date of enrolment through study completion, minimum follow-up 2 years."},{"measure":"Myocardial Infarction","timeFrame":"From the date of enrolment through study completion, minimum follow-up 2 years."},{"measure":"Heart Failure","timeFrame":"From the date of enrolment through study completion, minimum follow-up 2 years."},{"measure":"Health Economics","description":"Mean differences in health care cost, and 2-year quality-adjusted survival based on EuroQol-5D-5L between the treatment groups, combined into an incremental cost-effectiveness ratio.","timeFrame":"From the date of enrolment through study completion, minimum follow-up 2 years."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Patients with diagnosis of atrial fibrillation, including newly diagnosed, with or without current oral anticoagulant treatment\n2. Signed informed consent\n\nExclusion criteria:\n\n1. Contraindication for any oral anticoagulant, according to the SmPC (in Sweden FASS)\n2. Indication for oral anticoagulant treatment beyond atrial fibrillation, e.g. venous thromboembolism and/or mechanical heart valve prosthesis\n3. Currently on treatment with a non-vitamin K antagonist oral anticoagulant (NOAC) and not eligible for change of NOAC drug e.g. drug-drug interactions\n4. Concomitant dual antiplatelet treatment\n5. Acute coronary syndrome (myocardial infarction or unstable angina) within the last 30 days\n6. Participation in anti-thrombotic pharmaceutical trial\n7. Planned for AF ablation or AF surgery\n8. Haemoglobin \\<90 g/L\n9. Patients who, in the opinion of the investigator, cannot or will not comply with the requirements of the protocol","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Jonas Oldgren, MD, PhD","affiliation":"Uppsala Clinical Reseach Center, UCR","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Uppsala University Hospital","city":"Uppsala","country":"Sweden","geoPoint":{"lat":59.85882,"lon":17.63889}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M3934","name":"Anticoagulants","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}